Kasper B - Search Results

1

Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS).

Ronellenfitsch U, Dimitrakopoulou-Strauss A, Jakob J, Kasper B, Nowak K, Pilz LR, Attenberger U, Gaiser T, Egerer G, Fröhling S, Derigs HG, Schwarzbach M, Hohenberger P. Ronellenfitsch U, et al. Among authors: kasper b. BMJ Open. 2016 Jan 6;6(1):e009558. doi: 10.1136/bmjopen-2015-009558. BMJ Open. 2016. PMID: 26739732 Free PMC article. Clinical Trial.

2

Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?

Kasper B, Harter C, Meissner J, Bellos F, Krasniqi F, Ho AD, Egerer G. Kasper B, et al. Support Care Cancer. 2004 Mar;12(3):205-7. doi: 10.1007/s00520-003-0573-2. Epub 2004 Jan 16. Support Care Cancer. 2004. PMID: 14727169

3

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.

Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. Kasper B, et al. Bone Marrow Transplant. 2004 Jul;34(1):37-41. doi: 10.1038/sj.bmt.1704520. Bone Marrow Transplant. 2004. PMID: 15170176

4

Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?

Kasper B, Ho AD, Egerer G. Kasper B, et al. Oncology. 2005;68(2-3):115-21. doi: 10.1159/000085704. Epub 2005 May 9. Oncology. 2005. PMID: 15886503 Review.

5

A new therapeutic approach in patients with advanced sarcoma.

Kasper B, Ho AD, Egerer G. Kasper B, et al. Int J Clin Oncol. 2005 Dec;10(6):438-40. doi: 10.1007/s10147-005-0514-9. Int J Clin Oncol. 2005. PMID: 16369750

6

Treatment of gastrointestinal stromal tumor with imatinib mesylate: a retrospective single-center experience in Heidelberg.

Kasper B, Kallinowski B, Herrmann T, Lehnert T, Mechtersheimer G, Geer T, Ho AD, Egerer G. Kasper B, et al. Dig Dis. 2006;24(1-2):207-11. doi: 10.1159/000090322. Dig Dis. 2006. PMID: 16699280

7

Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.

Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U. Kasper B, et al. Leuk Lymphoma. 2007 Apr;48(4):746-53. doi: 10.1080/10428190601113568. Leuk Lymphoma. 2007. PMID: 17454633

8

Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?

Kasper B, Gil T, Awada A. Kasper B, et al. Curr Opin Oncol. 2007 Jul;19(4):336-40. doi: 10.1097/CCO.0b013e32812143ef. Curr Opin Oncol. 2007. PMID: 17545796 Review.

9

Dose-intensive chemotherapy with stem cell support as a treatment strategy for bone and soft-tissue sarcomas.

Kasper B, Ho AD, Egerer G. Kasper B, et al. Curr Stem Cell Res Ther. 2006 Jan;1(1):29-35. doi: 10.2174/157488806775269098. Curr Stem Cell Res Ther. 2006. PMID: 18220851

10

Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.

Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, Egerer G. Kasper B, et al. Onkologie. 2008 Mar;31(3):107-12. doi: 10.1159/000113795. Epub 2008 Feb 8. Onkologie. 2008. PMID: 18322413 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

295 results

Search Page

Filters